Bio-Path Holdings

Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.
Company Growth (employees)
Bellaire, US
Size (employees)
11 (est)
Bio-Path Holdings was founded in 2011 and is headquartered in Bellaire, US

Bio-Path Holdings Office Locations

Bio-Path Holdings has an office in Bellaire
Bellaire, US (HQ)
210 4710 Bellaire Blvd

Bio-Path Holdings Metrics

Bio-Path Holdings Financial Metrics

Revenue (2016)

$13 k

Net income (2016)

($6.8 m)

Market capitalization (21-Mar-2017)

$78.4 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$9.4 m
Bio-Path Holdings's current market capitalization is $78.4 m.
Bio-Path Holdings's revenue was reported to be $13 k in 2016
FY, 2013FY, 2014FY, 2015Y, 2016


$13 k

Operating expense total

$15.7 m$4.5 m$5.5 m$8.5 m


($15.7 m)($4.5 m)($5.5 m)($8.5 m)

EBIT margin, %


Interest income

$4 k$22.6 k$17.7 k$12 k

Pre tax profit

($3.3 m)($4.5 m)($5.5 m)

Income tax expense

Net Income

($15.4 m)($4.5 m)($5.5 m)($6.8 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$3.6 m$13.9 m$8.9 m$9.4 m

Accounts Receivable


Current Assets

$3.7 m$14.1 m$9.6 m$10.7 m


$113.1 k$72 k$614 k

Total Assets

$5.1 m$15.5 m$10.8 m$12.2 m

Accounts Payable

$76.1 k$41 k$54.6 k$69 k

Current Liabilities

$294.9 k$562 k$937.4 k$1.1 m

Additional Paid-in Capital

$20.1 m$34.7 m$35.1 m$40.3 m

Retained Earnings

($19.9 m)($25.4 m)($32.1 m)

Total Equity

$4.8 m$14.9 m$9.8 m$8.2 m

Financial Leverage

1.1 x1 x1.1 x1.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($3.3 m)($4.5 m)($5.5 m)($6.8 m)

Depreciation and Amortization

$10.3 k$41.1 k$43 k

Accounts Receivable


Accounts Payable

($34.3 k)$267.1 k$375.4 k($146 k)

Cash From Operating Activities

($2.3 m)($3.8 m)($5 m)($8.1 m)

Cash From Investing Activities

($123.4 k)($338 k)

Cash From Financing Activities

$5.3 m$14.2 m$9 m

Interest Paid

Income Taxes Paid

Bio-Path Holdings Market Value History

Bio-Path Holdings News

Bio-Path Holdings Company Life

You may also be interested in